Immunological Roles of CCL18 in Pan‑Cancer and Its Potential Value in Endometrial Cancer

• Published in: Molecular biotechnology
• Main Authors: Wang, Cangxue, Yang, Yuxiang, Li, Donghao, Guan, Yihao, Cao, MengYuan, Nie, Manjie, Sun, Caowei, Fu, Wenke, Kong, Xuhui
• Format: Journal Article
• Language: English
• Published: Switzerland 30.05.2024
• Subjects: Endometrial cancer; CCL18; Immune
• ISSN: 1073-6085; 1559-0305
• DOI: 10.1007/s12033-024-01205-7

Endometrial cancer (EC) is one of the most prevalent malignancies in the female reproductive system. However, the potential functions and mechanisms of immune-related genes in the onset and progression of EC remain unclear. The immune-related gene CCL18 has been implicated in apoptosis, proliferation, invasion, metastasis, and drug resistance in various types of tumors. Nevertheless, its role in pan-cancer has been poorly investigated, and its expression value and prognostic significance in endometrial cancer (EC) have not been explored. Therefore, the objective of this study was to identify potential immune-related prognostic biomarkers for EC by utilizing the cancer genome atlas (TCGA), immunology database and analysis portal (ImmPort) database, and Gene Expression Omnibus (GEO). Immunohistochemistry staining results from EC tissue chips demonstrated elevated expression levels of inflammatory chemokine protein 18 (CCL18) in EC compared to normal endometrium. This study offers a potential therapeutic strategy for EC treatment by identifying regulatory targets through microRNA sequencing data. Additionally, drug prediction was based on CCL18 targets. Furthermore, an analysis of CCL18 expression in pan-cancer was conducted, and the results revealed its high expression in various types of cancer, including EC and bladder cancer. Through analysis of the ATAC-seq data, we found that SIX1, SOX3, and TWIST2 may regulate CCL18 transcription by binding to the gene promoter of CCL18 in EC. This study indicated that CCL18 could be a potential biomarker in pan-cancer and EC.